As of 2025-07-01, the EV/EBITDA ratio of Summit Therapeutics Inc (SMMT) is -27.11. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SMMT's latest enterprise value is 15,592.49 mil USD. SMMT's TTM EBITDA according to its financial statements is -575.12 mil USD. Dividing these 2 quantities gives us the above SMMT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2025-06-27 | -26.23 |
| 2025-06-26 | -27.16 |
| 2025-06-25 | -27.10 |
| 2025-06-24 | -26.65 |
| 2025-06-23 | -25.96 |
| 2025-06-20 | -26.18 |
| 2025-06-18 | -25.67 |
| 2025-06-17 | -25.27 |
| 2025-06-16 | -25.39 |
| 2025-06-13 | -25.17 |
| 2025-06-12 | -25.67 |
| 2025-06-11 | -24.92 |
| 2025-06-10 | -28.14 |
| 2025-06-09 | -27.47 |
| 2025-06-06 | -26.22 |
| 2025-06-05 | -25.11 |
| 2025-06-04 | -24.89 |
| 2025-06-03 | -26.26 |
| 2025-06-02 | -22.52 |
| 2025-05-30 | -23.15 |
| 2025-05-29 | -33.48 |
| 2025-05-28 | -33.26 |
| 2025-05-27 | -32.74 |
| 2025-05-23 | -33.01 |
| 2025-05-22 | -32.91 |
| 2025-05-21 | -32.45 |
| 2025-05-20 | -31.13 |
| 2025-05-19 | -30.64 |
| 2025-05-16 | -30.46 |
| 2025-05-15 | -29.45 |
| 2025-05-14 | -29.01 |
| 2025-05-13 | -31.41 |
| 2025-05-12 | -32.25 |
| 2025-05-09 | -30.57 |
| 2025-05-08 | -31.46 |
| 2025-05-07 | -31.00 |
| 2025-05-06 | -30.88 |
| 2025-05-05 | -35.82 |
| 2025-05-02 | -35.66 |
| 2025-05-01 | -31.49 |
| 2025-04-30 | -30.78 |
| 2025-04-29 | -30.13 |
| 2025-04-28 | -30.77 |
| 2025-04-25 | -29.93 |
| 2025-04-24 | -47.02 |
| 2025-04-23 | -42.54 |
| 2025-04-22 | -34.95 |
| 2025-04-21 | -32.20 |
| 2025-04-17 | -31.41 |
| 2025-04-16 | -29.40 |